ARCA biopharma appoints Jacob Ma-Weaver, from largest shareholder, to board; explores strategic alternatives

Oruka Therapeutics, Inc.

Jacob Ma-Weaver appointed as Class III director effective June 15, 2022, term through 2024 annual meeting.
Ma-Weaver is managing member of Cable Car Capital, ARCA's largest shareholder.
Cooperation agreement includes standstill until 180 days after Ma-Weaver leaves board or 90 days before 2023 annual meeting.
Company to explore and evaluate strategic options to maximize stockholder value.
Ma-Weaver granted option to purchase 12,000 shares at $2.27 per share, vesting over 36 months.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jacob Ma-Weaver

director

ORKA · Oruka Therapeutics, Inc.

Effective: 2022-06-15
Filed: June 21, 2022, 7:59 PM ET

On June 15, 2022, the Board of the Company elected Jacob Ma‐Weaver as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jacob Ma-Weaver was elected as director at Oruka Therapeutics, Inc..

Action: elected
Role: director

Exact text from the filing

On June 15, 2022, the Board of the Company elected Jacob Ma‐Weaver as a director of the Company.

View on SEC.gov

Oruka Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-023734

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.